Daiichi Sankyo and NGM Biopharmaceuticals agreed to jointly develop therapeutic candidates that modulate beta-cell growth and function for potential treatment of type 1 and type 2 diabetes. Daiichi will oversee preclinical testing, development, production and commercialization of products worldwide. It will also keep global licensing rights to products resulting from the collaboration. NGM will receive an upfront payment and research funding, plus milestone fees and sales royalties.
Published in Brief: